Guardant Health Market Cap 2017-2022 | GH

Guardant Health market cap history and chart from 2017 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Guardant Health market cap as of March 21, 2023 is $2.66B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.664B $0.450B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.298B 9.44
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.439B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.570B 0.00
Arcus Biosciences (RCUS) United States $1.208B 0.00
Biohaven (BHVN) United States $0.950B 0.00
Emergent Biosolutions (EBS) United States $0.405B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.161B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00
Gelesis Holdings (GLS) United States $0.015B 0.00